Kazano® Tablets for Type 2 Diabetes (Alogliptin/Metformin)

What Kazano® Is and How It Works

Kazano is a prescription tablet that combines alogliptin (a DPP-4 inhibitor) and metformin (a biguanide) for adults with type 2 diabetes. It helps lower blood sugar when diet and exercise alone are not enough. People often compare Kazano price across pharmacies, and Kazano cost without insurance can vary by source and strength. CanadianInsulin is a prescription referral service. Prescriptions are verified with your clinic, and orders are filled by licensed Canadian pharmacies. We work with vetted partner pharmacies to source authentic brand medications at value-focused pricing across a broad selection.

Alogliptin increases incretin levels to boost insulin release and reduce glucagon after meals. Metformin reduces hepatic glucose output and improves insulin sensitivity. Together, they lower fasting and post‑meal glucose with a low risk of hypoglycemia when not used with insulin or sulfonylureas. Tablets are taken by mouth, usually twice daily with meals. Strengths align with common metformin doses (for example, 12.5/500 mg, 12.5/850 mg, 12.5/1000 mg), selected by the prescriber. Learn more about Type 2 Diabetes.

Dosage and Usage

• Initiation: Start based on current therapy and renal function. If switching from separate agents, match the total daily metformin dose and provide alogliptin to a total of 25 mg per day.
• Titration: Increase metformin component gradually to limit gastrointestinal effects. The usual maximum is metformin 2000 mg/day and alogliptin 25 mg/day, as tolerated.
• Administration: Take with morning and evening meals. Swallow tablets whole with water. Do not crush or split unless advised by the prescriber.
• Renal function: Dose selection requires renal assessment. Metformin is not recommended in severe renal impairment. Alogliptin may require dose adjustments with reduced eGFR.
• Iodinated contrast/surgery: Temporarily stop metformin-containing products around contrast imaging or procedures when indicated; restart after renal function is re‑evaluated.
• Missed dose: If a dose is missed, take the next dose at the regular time. Do not double up.
• Concomitant agents: Consider lowering the dose of insulin or sulfonylureas to reduce hypoglycemia risk when used together.
• Monitoring: Check fasting glucose and A1C regularly. Monitor renal function and vitamin B12 levels during long‑term metformin use.

• Storage: Keep at 20–25°C (68–77°F); excursions 15–30°C (59–86°F) are acceptable. Protect from moisture and heat. Store in the original, tightly closed container.
• Travel: Carry in your hand luggage with a copy of your prescription. Avoid leaving tablets in cars or direct sun. Keep desiccants in the bottle if supplied. Do not freeze.
• Daily use: Use a pill organizer if needed, and set reminders for consistent dosing.

Benefits and Savings

The alogliptin–metformin combination targets both fasting and post‑meal glucose. Many patients see meaningful A1C reductions compared with either component alone. The regimen is weight‑neutral overall, with metformin sometimes producing modest weight loss. Fixed‑dose tablets simplify therapy compared with multiple separate pills.

Convenience supports adherence. Twice‑daily dosing with meals fits common routines. The low intrinsic risk of hypoglycemia (when not combined with insulin or sulfonylureas) helps with day‑to‑day stability. Clinical studies show DPP‑4 inhibitors are generally well tolerated, and metformin remains a first‑line backbone for type 2 diabetes.

Many customers save 60–80% vs typical U.S. prices, including the kazano price without insurance. See our promotions page for current offers, including any kazano coupon if available.

Side Effects and Safety

• Common: diarrhea, nausea, stomach upset, gas, abdominal discomfort, decreased appetite.
• Other reported: headache, nasopharyngitis, upper respiratory tract infection, back pain, dizziness.
• Laboratory: possible vitamin B12 reduction with long‑term metformin.
• Hypoglycemia: more likely when used with insulin or sulfonylureas.

Serious risks are rare but include lactic acidosis with metformin (higher risk with significant renal impairment, hypoxia, dehydration, or heavy alcohol use), pancreatitis with DPP‑4 inhibitors (persistent severe abdominal pain), worsening heart failure in susceptible patients, severe skin reactions such as bullous pemphigoid, hepatic enzyme elevations, and hypersensitivity reactions (angioedema, anaphylaxis). Do not use for type 1 diabetes or diabetic ketoacidosis.

Onset Time

Many people notice fasting glucose improvements within the first week as metformin begins to work. Post‑meal readings can improve as alogliptin reaches steady state over several days. A1C reflects the prior three months of glycemia, so the full effect is usually seen after 8–12 weeks as the dose is optimized and adherence is steady.

Weight effects are generally neutral, with any metformin‑related change appearing gradually over several weeks. Stabilization of gastrointestinal tolerance often occurs as the metformin dose is titrated and taken with food.

Compare With Alternatives

Rybelsus® (oral semaglutide) is a GLP‑1 receptor agonist taken once daily. It can offer larger A1C and weight reductions than a DPP‑4 inhibitor, but gastrointestinal effects are more common, and administration requires specific fasting instructions.

Trulicity® (dulaglutide) is a once‑weekly injectable GLP‑1 receptor agonist. It provides robust glucose lowering and weight benefits, with pen devices designed for ease of use. It may suit those comfortable with injections and seeking fewer daily steps.

Mounjaro® (tirzepatide) is a once‑weekly injectable dual GIP/GLP‑1 agonist. Clinical data show strong A1C reductions and weight loss. It is an option when oral therapies and DPP‑4 inhibitors are insufficient for glycemic targets.

The best choice depends on goals, tolerance, and comorbidities. Some patients prefer an oral regimen like Kazano; others prioritize weight loss or once‑weekly dosing.

Combination Therapy

• With SGLT2 inhibitors (for example, empagliflozin): complementary glucose control with potential cardiovascular and renal benefits.
• With basal insulin: consider reducing insulin dose to limit hypoglycemia as control improves.
• With sulfonylureas: consider dose reduction to reduce the risk of low blood sugar.
• With statins, ACE inhibitors, or ARBs: address cardiovascular risk factors alongside glucose control.
• Avoid duplication with other DPP‑4 inhibitors. Review all medicines, including over‑the‑counter products and alcohol intake.

Patient Suitability and Cost‑Saving Tips

Kazano is for adults with type 2 diabetes who need better glycemic control despite diet and exercise. It is not indicated for type 1 diabetes or diabetic ketoacidosis. It should be avoided in severe renal impairment and in patients with acute or chronic metabolic acidosis.

Use caution in hepatic disease, conditions associated with hypoxia or dehydration, a history of pancreatitis, and in patients with heart failure. Review renal function before initiation and periodically thereafter. Discuss pregnancy and breastfeeding plans with a healthcare professional.

Cost‑saving ideas include choosing multi‑month quantities when appropriate, coordinating refills to ship together, and planning ahead to avoid last‑minute shipments. If placing a kazano online order or kazano online purchase, compare available strengths to match the prescribed dose efficiently. Patients watching for a kazano discount or kazano promo can check the promotions page periodically. Those using cash pay may compare Kazano tablets cost across strengths. Larger quantities can help when considering a kazano bulk order, if prescribed.

Authoritative Sources

FDA Drugs@FDA: Kazano (Alogliptin and Metformin) Application 203414

U.S. Prescribing Information and Medication Guide (Kazano)

Order Kazano® from CanadianInsulin: add to cart, upload your prescription, and we ship with prompt, express, cold‑chain handling.

This page is educational and does not replace medical advice. Always discuss personal treatment, risks, and dosing with a qualified healthcare professional.